OncoMatch

OncoMatch/Clinical Trials/NCT04106115

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Is NCT04106115 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including S-488210/S-488211 and Durvalumab for bladder cancer.

Phase 1/2RecruitingUniversity College, LondonNCT04106115Data as of Sep 2026Location: United Kingdom

Treatment: Durvalumab · S-488210/S-488211DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Durvalumab

Other

S-488210/S-488211

Cancer type

Urothelial Carcinoma

Performance status

WHO 0–1

Prior therapy

Cannot have received: anti-pd-1/pd-l1/ctla-4 monoclonal antibody or other novel immune-oncology agent

Cannot have received: allogeneic stem cell or solid organ transplantation

Lab requirements

Blood counts

haemoglobin ≥9.0 g/dl; absolute neutrophil count ≥1.5 x 10^9/l (≥150,000 per mm3); platelet count ≥100 x 10^9/l (≥100,000 per mm3); inr ≤1.5 and aptt ≤1.5 x uln (applies only to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)

Kidney function

measured creatinine clearance ≥40 ml/min or calculated creatinine clearance ≥40 ml/min using cockcroft-gault formula

Liver function

total bilirubin ≤1.5 x uln (<3.0 x uln for patients with gilbert's syndrome); ast or alt ≤2.5 x uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04106115 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior anti-pd-1/pd-l1/ctla-4 monoclonal antibody or other novel immune-oncology agent, allogeneic stem cell or solid organ transplantation disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify